Daniel O'Day is Chairman and Chief Executive Officer of Gilead Sciences, Inc. (GILD). The company reported total compensation of $28,437,198 for fiscal year 2025.
| Salary | $1,795,192 |
|---|---|
| Bonus | $0 |
| Stock awards | $15,238,402 |
| Option awards | $4,500,060 |
| Non-equity incentive plan | $4,848,120 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $2,055,424 |
| Total | $28,437,198 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Gilead Sciences, Inc. filed March 20, 2026, accession 0001308179-26-000106.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chairman and Chief Executive Officer | $1,795,192 | $0 | $15,238,402 | $4,500,060 | $4,848,120 | $0 | $2,055,424 | $28,437,198 |
| FY2024 | Chairman and Chief Executive Officer | $1,771,201 | — | $12,426,816 | $4,125,011 | $4,028,096 | — | $1,338,268 | $23,689,392 |
| FY2023 | Chairman and Chief Executive Officer | $1,740,962 | — | $11,865,090 | $3,749,966 | $4,036,200 | — | $1,215,472 | $22,607,690 |
| FY2022 | Chairman and Chief Executive Officer | $1,691,154 | — | $10,603,901 | $3,750,014 | $4,716,480 | — | $859,704 | $21,621,253 |
| FY2021 | Chairman and Chief Executive Officer | $1,650,000 | — | $9,764,060 | $3,375,004 | $3,446,190 | — | $994,212 | $19,229,466 |
| FY2020 | Chairman and Chief Executive Officer | $1,702,885 | — | $8,388,056 | $3,125,041 | $4,713,390 | — | $1,068,723 | $18,998,095 |
| FY2019 | Chairman and Chief Executive Officer | $1,267,692 | $5,675,000 | $15,500,541 | $3,000,002 | $3,120,000 | — | $544,619 | $29,107,854 |
Totals as disclosed in each year's own compensation disclosure for Gilead Sciences, Inc..
| Peer-group chief executive median | $24,169,562 |
|---|---|
| Difference from that median | $4,267,636 |
| Percentile within the disclosed peer group | 70th |
| Peers with a disclosed figure | 10 |
Medians and percentiles are computed across the peer group Gilead Sciences, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel O'Day this page | Chairman and Chief Executive Officer | $28,437,198 |
| Dietmar Berger | Chief Medical Officer | $13,922,878 |
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer | $9,300,643 |
| Andrew Dickinson | Chief Financial Officer | $8,765,616 |
| Deborah Telman | Former Executive Vice President, Corporate Affairs and General Counsel | $5,004,669 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Gilead Sciences, Inc. compensation brief.
Daniel O'Day's compensation sits inside Gilead Sciences, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.